These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27852643)

  • 21. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient.
    Oka K; Yakushiji T; Sato H; Hirai T; Yamashita Y; Mizuta H
    Skeletal Radiol; 2010 Feb; 39(2):141-6. PubMed ID: 19924412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
    Lindner NJ; Scarborough MT; Spanier SS; Enneking WF
    J Cancer Res Clin Oncol; 1998; 124(10):575-80. PubMed ID: 9829862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
    Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
    J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
    Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
    Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis.
    Bajpai J; Gamnagatti S; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Safaya R; Bakhshi S
    Pediatr Radiol; 2011 Apr; 41(4):441-50. PubMed ID: 20978754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Poor Responders to Neoadjuvant Chemotherapy in Patients with Osteosarcoma: Additive Value of Diffusion-Weighted MRI including Volumetric Analysis to Standard MRI at 3T.
    Lee SK; Jee WH; Jung CK; Im SA; Chung NG; Chung YG
    PLoS One; 2020; 15(3):e0229983. PubMed ID: 32155203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
    Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
    J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of intra-arterial chemotherapy and embolization before limb salvage surgery for osteosarcoma of the lower extremity.
    Zhang HJ; Yang JJ; Lu JP; Lai CJ; Sheng J; Li YX; Hao Q; Zhang SM; Gupta S
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):672-8. PubMed ID: 19296158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
    Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
    Ryoo I; Kim JH; Choi SH; Sohn CH; Kim SC
    Magn Reson Med Sci; 2015; 14(4):337-45. PubMed ID: 26104081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
    Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
    J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of histopathology and multi-modal magnetic resonance imaging in childhood osteosarcoma: Predicting tumor response to chemotherapy.
    Teo KY; Daescu O; Cederberg K; Sengupta A; Leavey PJ
    PLoS One; 2022; 17(2):e0259564. PubMed ID: 35157711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,
    Bacci G; Ferrari S; Bertoni F; Picci P; Bacchini P; Longhi A; Donati D; Forni C; Campanacci L; Campanacci M
    Clin Orthop Relat Res; 2001 May; (386):186-96. PubMed ID: 11347833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
    Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
    J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.